Developed Drugs

START researchers are among just a handful of scientists anywhere in the world who can claim direct involvement with the clinical development of many anticancer drugs that, in the past 25 years, have obtained FDA approval and are now considered a part of the standard of care. These drugs include:

​

• Navelbine (Vinorelbine®)

• Mixtoxantrone (Novantrone®)

• Irinotecan (Camptosar®)

• Docetaxel (Taxotere®)

• Gemcitabine (Gemzar®)

• Topotecan (Hycamtin®)

• Trastuzamab (Herceptin®)

• Cetuximab (Erbitux®)

• Erlotinib (Tarceva®)

• Gefitinib (Iressa®)

• Sorafenib (Nexavar®)

• Panitumumab (Vectibix®)

• Temsirolimus (Torisel®)

• Lapatinib (Tykerb®)

• Bortezomib (Velcade®)

• Vorinostat (Zolinza®)

• Pemetrexed (Alimta®)

• Abiraterone (Zytiga®)

• Ixabepilone (Ixempra®)

• Cabazitaxel (Jevtana®)

• Eribulin (Halaven®)

• Trametinib (Mekinist®)

• Trastuzumab Emtansine (Kadycla®)

• Regorafenib (Stivarga®)

• Ziv-Aflibercept (Zaltrap®)

• Carfilzomib (Kyprolisv)

• Pembrolizumab (Keytruda®)

• Cemiplimab (Libtayo®)